EMEA 2026 life sciences: UK equity and FDI shifts
Decision brief
Answer first · skim in under a minute
JLL's EMEA 2026 Life Sciences Industry & Cluster Report highlights strong public market performance, rising venture capital flows, and the transformative impact of AI on European life sciences clusters. The analysis provides actionable intelligence for pharma business development teams and investors navigating the evolving landscape.
EMEA life sciences capital is not a single JLL narrative. The UK’s 2026 Life Sciences Competitiveness Indicators show equity finance at £4.5 billion in 2024 and inward FDI up 164% to £2.1 billion—hard numbers BD and investors can underwrite while European clusters still compete for late-stage capital and reimbursed launches.
Contents10 sections
Key Takeaways
- UK life sciences equity finance rose to £4.5 billion in 2024 (+32% vs 2023), ranking third globally behind the USA and China.
- Inward UK life sciences FDI hit £2.1 billion in 2024, up 164% year on year, ranking fourth among 18 comparators.
- UK pharmaceutical exports slipped to £24.7 billion in 2024 (−4%), while pharma R&D by UK businesses was about 0.32–0.33% of GDP.
- Only one UK life sciences IPO closed in 2024, underscoring a public-market bottleneck despite private equity recovery.
What do the 2026 UK competitiveness indicators say?
The Office for Life Sciences published the Life Sciences Competitiveness Indicators 2026 on 19 March 2026 (updated 23 March 2026). There was no 2025 LSCI release. The summary benchmarks UK research, investment, production, and labour metrics against international peers using OECD and commercial datasets.
Primary source: Life sciences competitiveness indicators 2026: summary (GOV.UK) and the collection page Life sciences competitiveness indicators, 2026.
Where is EMEA capital concentrating in the data?
Equity finance raised by UK life sciences companies increased to £4.5 billion in 2024 from £3.4 billion in 2023. That is the highest reading since the 2021 pandemic-era peak and keeps the UK third globally behind only the USA and China. Inward FDI into UK life sciences rose to £2.1 billion in 2024, a 164% jump versus 2023 and a return toward 2021 levels after multi-year declines.
- Equity finance 2024: £4.5 billion (+32%)
- Global equity rank: 3rd (behind USA, China)
- Inward FDI 2024: £2.1 billion (+164%)
- FDI rank among 18 comparators: 4th (from 8th)
- UK life sciences IPOs in 2024: 1
Which export and R&D figures temper the growth story?
UK pharmaceutical exports fell from £25.6 billion in 2023 to £24.7 billion in 2024 (−4%), with the UK ranking eleventh globally in 2024. Medical technology exports were about £10.0 billion in 2024 (twelfth globally). Pharmaceutical imports rose 4% to £25.9 billion.
On R&D, business-enterprise pharmaceutical R&D was 0.32% of UK GDP in 2023 among countries with comparable OECD coverage; ONS-linked 2024 UK-only figures put pharmaceuticals R&D near £9.3 billion (about 0.33% of GDP and 17% of UK business R&D spend).
How should BD teams translate cluster metrics into diligence?
Cluster heat maps matter only if capital converts into trials, manufacturing, and paid access. Pair UK equity/FDI recovery with EMA review timelines and NICE appraisal queues when sizing EU-5 launch risk. Manufacturing and packaging capacity stories in Europe remain relevant for supply diligence even when public markets stay thin.
For regulatory pacing, monitor EMA human medicines news and guidance hubs such as the EMA news feed. For England market-access sequencing, start with NICE technology appraisal pathways rather than private cluster brochures.
What remains unproven from private cluster reports?
Third-party commercial cluster reports (including real-estate broker surveys) are useful for site selection hypotheses but are not allowlisted primary evidence for this article’s hard numbers. Claims about AI transforming every European cluster, or about specific park-level occupancy rates, are omitted unless confirmed in GOV.UK, EMA, or NICE sources.
What should investors watch next in 2026?
Watch whether UK equity raises stay above the £4 billion mark, whether FDI rankings hold if US and EU rates shift, and whether IPO supply recovers from a single 2024 deal. On the product side, EMA CHMP opinions and NICE guidance remain the gate from cluster capital to reimbursed revenue.
Related NovaPharma coverage
- Maersk Europe market update June 2026: pharma supply chains
- Regulatory round-up: 2 February 2026
- World lightproof bottle opaque liners market: pharma growth to 2035
Frequently Asked Questions
What do the 2026 UK life sciences competitiveness indicators show on equity finance?
Office for Life Sciences data in the 2026 LSCI summary show UK life sciences equity finance rose to £4.5 billion in 2024, up 32% from £3.4 billion in 2023, keeping the UK third globally behind only the USA and China.
How did UK life sciences FDI change in 2024?
Inward life sciences FDI into the UK reached £2.1 billion in 2024, a 164% increase versus 2023, lifting the UK’s ranking among 18 comparator countries to fourth from eighth.
What should EMEA BD teams watch beyond UK equity totals?
Track pharmaceutical export soft spots (£24.7 billion in 2024, −4%), thin IPO supply (one UK life sciences IPO in 2024), and EU regulatory timelines via EMA and NICE pathways that convert cluster capital into reimbursed products.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
